EASL 2018 FRI-320
The effect of PEG-IFN add on or switch to on HBsAg clearance in
HBeAg- CHB patients recieving entecavir treatment
L. Yan, Y. Xu, L. Chen, Y. Ding, Q. Xie, H. Wang. Shanghai Jiaotong
University School, Department of Infectious Diseases and Hepatology,
Shanghai, China
Email: [email protected]
Background and Aims: Chronic hepatitis B (CHB) patients rarely
achieve HBsAg loss with nucleoside/nucleotide analogue (NA)
therapy. It was evaluated HBsAg loss in HBeAg− patients with
entecavir switched to or added on pegylated interferon (PEG-IFN) in a
retrospective study.
Method: Totally 87 HBeAg− CHB patients treated with entecavir for
24weekswere studied, 21 switched to PEG-IFN,13 added on PEG-IFN
and 53 continued entecavir therapy (ETV group).
Results: HBsAg clearance at week 48 was reported in 2/21 (10%)
patients in switch-to group, 2/13 (15%) patients in add-on group;
whereas none was in ETV group. HBsAg reduction at week 48 was
1.055logIU/ml, 0.6452 logIU/ml or 0.014 logIU/ml respectively in
switch-to, add-on, or ETV group. The response rate of switch-to, addon
and ETV monotherapy was, 44%, 38% or 2%, respectively. It was
analysed that age, BMI, ALT, AST, PLT, liver stiffness, HBsAg titer at
baseline, or HBsAg reduction at 24-week, showing that HBsAg titers at
baseline and HBsAg reduction atweek 24were associatedwith HBsAg
reduction and clearance. HBsAg reduction was associated with the
response rate atweek24, showing thatROCCurve analyse the response
versus HBsAg atweek 48, the AUROCwas 0.865. The PPV for response
was 70% and NPV was 100% with the cut-off value 0.2logIU/ml.
Conclusion: In summary, we demonstrated that PEG-IFN enhanced
HBsAg loss in HBeAg−CHB population. Patients with HBsAg titers at
baseline less than 1000 IU/ml and HBsAg reduction more than
0.2logIU/ml achieved HBsAg loss with a higher chance. 作者: StephenW 时间: 2018-4-6 08:39
EASL 2018 FRI-320
The effect of PEG-IFN add on or switch to on HBsAg clearance in HBeAg- CHB patients recieving entecavir treatment
L. Yan, Y. Xu, L. Chen, Y. Ding, Q. Xie, H. Wang. Shanghai Jiaotong University School, Department of Infectious Diseases and Hepatology,
Shanghai, China
Email: [email protected]
Background and Aims:
Chronic hepatitis B (CHB) patients rarely achieve HBsAg loss with nucleoside/nucleotide analogue (NA) therapy. It was evaluated HBsAg loss in HBeAg− patients with entecavir switched to or added on pegylated interferon (PEG-IFN) in a retrospective study.
Method:
Totally 87 HBeAg− CHB patients treated with entecavir for 24weekswere studied, 21 switched to PEG-IFN,13 added on PEG-IFN and 53 continued entecavir therapy (ETV group).
Results:
HBsAg clearance at week 48 was reported in 2/21 (10%) patients in switch-to group, 2/13 (15%) patients in add-on group; whereas none was in ETV group. HBsAg reduction at week 48 was 1.055logIU/ml, 0.6452 logIU/ml or 0.014 logIU/ml respectively in switch-to, add-on, or ETV group. The response rate of switch-to, addon
and ETV monotherapy was, 44%, 38% or 2%, respectively. It was analysed that age, BMI, ALT, AST, PLT, liver stiffness, HBsAg titer at baseline, or HBsAg reduction at 24-week, showing that HBsAg titers at baseline and HBsAg reduction atweek 24were associatedwith HBsAg reduction and clearance. HBsAg reduction was associated with the response rate atweek24, showing thatROCCurve analyse the response versus HBsAg atweek 48, the AUROCwas 0.865. The PPV for response was 70% and NPV was 100% with the cut-off value 0.2logIU/ml.
Conclusion:
In summary, we demonstrated that PEG-IFN enhanced HBsAg loss in HBeAg−CHB population. Patients with HBsAg titers at baseline less than 1000 IU/ml and HBsAg reduction more than 0.2logIU/ml achieved HBsAg loss with a higher chance.
